Julie A Demartino

US Patent:

20020192214, Dec 19, 2002

Filed:

Aug 6, 2001

Appl. No.:

09/922895

Inventors:

Bruce Daugherty - South Orange NJ, US
Julie Demartino - Cranford NJ, US
Salvatore Siciliano - East Brunswick NJ, US
Martin Springer - Westfield NJ, US

Assignee:

Merck & Co., Inc.

International Classification:

A61K039/395
C07H021/04
C12P021/02
C12N005/06
C07K014/725

US Classification:

424/144100, 435/069100, 435/325000, 435/320100, 530/350000, 536/023500

Abstract:

The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human -chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.

US Patent:

20050033024, Feb 10, 2005

Filed:

Jan 29, 2004

Appl. No.:

10/767521

Inventors:

Bruce Daugherty - South Orange NJ, US
Julie Demartino - Cranford NJ, US
Salvatore Siciliano - East Brunswick NJ, US
Martin Springer - Westfield NJ, US

International Classification:

C07K014/705
C07H021/04

US Classification:

530350000, 536023500, 435069100, 435320100, 435325000

Abstract:

The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human β-chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.

US Patent:

20050079176, Apr 14, 2005

Filed:

Jan 22, 2003

Appl. No.:

10/501999

Inventors:

Richard Pierson III - Ruxton MD, US
Agnes Azimzadeh - Timonium MD, US
Carsten Schroeder - Baltimore MD, US
Julie DeMartino - Westfield NJ, US

International Classification:

A61K039/395
A61K038/00
A61K031/00

US Classification:

424145100, 514001000, 514002000

Abstract:

The use of chemokine receptor CCR5 modulators (e.g., CCR5 antagonists) is disclosed for the treatment or prevention of stress response (e.g., fever) in a subject resulting from surgery, infection or other insult to the subject (e.g., a warm-blooded vertebrate). Methods for treating or preventing disorders involving the activation of pro-inflammatory cytokines by administration of a CCR5 modulator, for inhibiting the endogenous production of pro-inflammatory cytokines by the administration of CCR5 modulators, and for determining the efficacy of CCR5 modulators in correcting abnormal levels of pro-inflammatory cytokines are also disclosed.

US Patent:

20060030582, Feb 9, 2006

Filed:

Apr 8, 2005

Appl. No.:

11/102417

Inventors:

Julie DeMartino - Westfield NJ, US
Taro Akiyama - Freehold NJ, US
Mary Struthers - Edison NJ, US
Lihu Yang - Edison NJ, US
Joel Berger - Hoboken NJ, US
Gregori Morriello - Randolph NJ, US
Alexander Pastemak - Princeton NJ, US
Changyou Zhou - Plainsboro NJ, US
Sander Mills - , US
Gabor Butora - Martinsville NJ, US
Shankaran Kothandaraman - Kendall Park NJ, US
Deodialsingh Guiadeen - Linden NJ, US
Cheng Tang - East Brunswick NJ, US
Richard Jiao - Havertown PA, US
Stephen Goble - West Windsor NJ, US
Christopher Moyes - Hertfordshire, GB

International Classification:

A61K 31/4745

US Classification:

514300000

Abstract:

The present invention is directed to methods for treating, preventing, ameliorating, controlling or reducing the risk of a disorder or disease, which method comprises the administration to a patient of an effective amount of the compound of formula I: I (wherein R, R, R, R, R, R, R, R, R, R, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

US Patent:

20070065849, Mar 22, 2007

Filed:

Aug 1, 2006

Appl. No.:

11/497543

Inventors:

Bruce Daugherty - South Orange NJ, US
Julie Demartino - Cranford NJ, US
Salvatore Siciliano - East Brunswick NJ, US
Martin Springer - Westfield NJ, US

International Classification:

C12Q 1/68
G01N 33/567
C07H 21/04
C12P 21/06
C07K 14/705

US Classification:

435006000, 435069100, 435320100, 435325000, 530350000, 536023500, 435007200

Abstract:

The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human β-chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.

US Patent:

20080194548, Aug 14, 2008

Filed:

Jan 5, 2006

Appl. No.:

11/794857

Inventors:

Michael J. Forrest - Shrewsbury NJ, US
Julie A. DeMartino - Westfield NJ, US
Michelle R. Flicker - Bridgewater NJ, US
Augustin Melian - Woodcliff Lake NJ, US
Samina Kanwar - Hoboken NJ, US
Gary J. Romano - Wynnewood PA, US

International Classification:

A61K 31/536
A61K 31/4375
A61K 31/351
A61K 31/40
A61P 11/00
A61P 9/10

US Classification:

5142305, 514300, 514460, 514423

Abstract:

A combination of a CCR2 antagonist and a statin is useful in the treatment and or prevention of inflammatory and other disorders, and methods of treating inflammatory and other disorders using a combination of a CCR2 antagonist and a statin.

US Patent:

20090191552, Jul 30, 2009

Filed:

Jun 22, 2007

Appl. No.:

12/227719

Inventors:

Kalpit A. Vora - Yardley PA, US
Julie A. DeMartino - Westfield NJ, US
John Stuart Mudgett - Basking Ridge NJ, US
Gene Porter - Neptune NJ, US
Gloria Wolfe - New York NY, US

International Classification:

C12Q 1/68
C12N 9/24
C07H 21/00
C12N 15/63
C12N 5/10

US Classification:

435 6, 435200, 536 232, 4353201, 435325

Abstract:

Described herein is a variant human acidic mammalian chitinase (AMCase) enzyme having improved stability and an isolated nucleic acid sequence which encodes the variant. The invention also provides to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing recombinant variant AMCase polypeptide and its use in screening assays to identify modulators.

US Patent:

62713477, Aug 7, 2001

Filed:

Apr 24, 1997

Appl. No.:

8/847296

Inventors:

Bruce L. Daugherty - South Orange NJ
Julie A. Demartino - Cranford NJ
Salvatore J. Siciliano - East Brunswick NJ
Martin S. Springer - Westfield NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07K 14715
C12N 510
C12N 1512
C12N 1564

US Classification:

530350

Abstract:

The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human. beta. -chemokine receptor and has been designated "CC CKR3". The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.